Biblio

Export 751 results:
Author Title [ Type(Desc)] Year
Filters: First Letter Of Keyword is P  [Clear All Filters]
Journal Article
A. Benaque, Gurruchaga, M. Jone, Abdelnour, C., Hernandez, I., Cañabate, P., Alegret, M., Rodríguez, I., Rosende-Roca, M., Tartari, J. Pablo, Esteban, E., López, R., Gil, S., Vargas, L., Mauleón, A., Espinosa, A., Ortega, G., Sanabria, Á., Pérez, A., Alarcón, E., González-Pérez, A., Marquié, M., Valero, S., Tárraga, L., Ruiz, A., and Boada, M., “Dementia Care in Times of COVID-19: Experience at Fundació ACE in Barcelona, Spain.”, J Alzheimers Dis, vol. 76, no. 1, pp. 33-40, 2020.
A. D. Korczyn, “Dementia in the COVID-19 Period.”, J Alzheimers Dis, vol. 75, no. 4, pp. 1071-1072, 2020.
A. D. Korczyn, “Dementia in the COVID-19 Period.”, J Alzheimers Dis, vol. 75, no. 4, pp. 1071-1072, 2020.
N. L. Olson and Albensi, B. C., “Dementia-Friendly "Design": Impact on COVID-19 Death Rates in Long-Term Care Facilities Around the World.”, J Alzheimers Dis, vol. 81, no. 2, pp. 427-450, 2021.
K. Talbot, Wang, H. - Y., Kazi, H., Han, L. - Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., Arvanitakis, Z., Schneider, J. A., Wolf, B. A., Bennett, D. A., Trojanowski, J. Q., and Arnold, S. E., “Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.”, J Clin Invest, vol. 122, no. 4, pp. 1316-38, 2012.
K. Talbot, Wang, H. - Y., Kazi, H., Han, L. - Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., Arvanitakis, Z., Schneider, J. A., Wolf, B. A., Bennett, D. A., Trojanowski, J. Q., and Arnold, S. E., “Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.”, J Clin Invest, vol. 122, no. 4, pp. 1316-38, 2012.
K. Talbot, Wang, H. - Y., Kazi, H., Han, L. - Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., Arvanitakis, Z., Schneider, J. A., Wolf, B. A., Bennett, D. A., Trojanowski, J. Q., and Arnold, S. E., “Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.”, J Clin Invest, vol. 122, no. 4, pp. 1316-38, 2012.
J. Ku Chung, Plitman, E., Nakajima, S., M Chakravarty, M., Caravaggio, F., Takeuchi, H., Gerretsen, P., Iwata, Y., Patel, R., Mulsant, B. H., and Graff-Guerrero, A., “Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 49, no. 3, pp. 743-54, 2016.
M. Barbera, Mangialasche, F., Jongstra, S., Guillemont, J., Ngandu, T., Beishuizen, C., Coley, N., Brayne, C., Andrieu, S., Richard, E., Soininen, H., and Kivipelto, M., “Designing an Internet-Based Multidomain Intervention for the Prevention of Cardiovascular Disease and Cognitive Impairment in Older Adults: The HATICE Trial.”, J Alzheimers Dis, vol. 62, no. 2, pp. 649-663, 2018.
T. Guieysse, Lamothe, R., Houot, M., Razafimahatratra, S., Medani, T., Lejeune, F. - X., Dreyfus, G., Klarsfeld, A., Pantazis, D., Koechlin, E., and Andrade, K., “Detecting Anosognosia from the Prodromal Stage of Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 4, pp. 1723-1733, 2023.
H. B. Mehta, Mehta, V., Tsai, C. - L., Chen, H., Aparasu, R. R., and Johnson, M. L., “Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension.”, J Alzheimers Dis, vol. 49, no. 2, pp. 423-32, 2016.
H. B. Mehta, Mehta, V., Tsai, C. - L., Chen, H., Aparasu, R. R., and Johnson, M. L., “Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension.”, J Alzheimers Dis, vol. 49, no. 2, pp. 423-32, 2016.
H. B. Mehta, Mehta, V., Tsai, C. - L., Chen, H., Aparasu, R. R., and Johnson, M. L., “Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension.”, J Alzheimers Dis, vol. 49, no. 2, pp. 423-32, 2016.
Z. Liu, Kameshima, N., Nanjo, T., Shiino, A., Kato, T., Shimizu, S., Shimizu, T., Tanaka, S., Miura, K., and Tooyama, I., “Development of a High-Sensitivity Method for the Measurement of Human Nasal Aβ42, Tau, and Phosphorylated Tau.”, J Alzheimers Dis, vol. 62, no. 2, pp. 737-744, 2018.
Z. Liu, Kameshima, N., Nanjo, T., Shiino, A., Kato, T., Shimizu, S., Shimizu, T., Tanaka, S., Miura, K., and Tooyama, I., “Development of a High-Sensitivity Method for the Measurement of Human Nasal Aβ42, Tau, and Phosphorylated Tau.”, J Alzheimers Dis, vol. 62, no. 2, pp. 737-744, 2018.
J. H. Lingler, Butters, M. A., Gentry, A. L., Hu, L., Hunsaker, A. E., Klunk, W. E., Mattos, M. K., Parker, L. A., J Roberts, S., and Schulz, R., “Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 52, no. 1, pp. 17-24, 2016.
J. H. Lingler, Butters, M. A., Gentry, A. L., Hu, L., Hunsaker, A. E., Klunk, W. E., Mattos, M. K., Parker, L. A., J Roberts, S., and Schulz, R., “Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 52, no. 1, pp. 17-24, 2016.
J. H. Lingler, Butters, M. A., Gentry, A. L., Hu, L., Hunsaker, A. E., Klunk, W. E., Mattos, M. K., Parker, L. A., J Roberts, S., and Schulz, R., “Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 52, no. 1, pp. 17-24, 2016.
G. M. McKhann, Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., Mohs, R. C., Morris, J. C., Rossor, M. N., Scheltens, P., Carrillo, M. C., Thies, B., Weintraub, S., and Phelps, C. H., “The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 263-9, 2011.
M. S. Albert, DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., Snyder, P. J., Carrillo, M. C., Thies, B., and Phelps, C. H., “The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 270-9, 2011.
M. Schjnning Nielsen, Simonsen, A. Hviid, Siersma, V., Hasselbalch, S. Gregers, and Hoegh, P., “The Diagnostic and Prognostic Value of a Dual-Tasking Paradigm in a Memory Clinic.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1189-1199, 2018.
M. Schjnning Nielsen, Simonsen, A. Hviid, Siersma, V., Hasselbalch, S. Gregers, and Hoegh, P., “The Diagnostic and Prognostic Value of a Dual-Tasking Paradigm in a Memory Clinic.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1189-1199, 2018.
E. Niemantsverdriet, Goossens, J., Struyfs, H., Martin, J. - J., Goeman, J., De Deyn, P. Paul, Vanderstichele, H., and Engelborghs, S., “Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 97-106, 2016.
E. Niemantsverdriet, Goossens, J., Struyfs, H., Martin, J. - J., Goeman, J., De Deyn, P. Paul, Vanderstichele, H., and Engelborghs, S., “Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 97-106, 2016.
O. Bousiges, Cretin, B., Lavaux, T., Philippi, N., Jung, B., Hezard, S., Heitz, C., Demuynck, C., Gabel, A., Martin-Hunyadi, C., and Blanc, F., “Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.

Pages